Medibank just raised its dividend. Here's what you need to know

Medibank just raised its dividend for the sixth year in a row.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's a huge day for earnings on the ASX this Thursday. This session has seen a bevy of ASX 200 shares deliver their latest numbers to investors. We've heard from Telstra Group Ltd (ASX: TLS), Wesfarmers Ltd (ASX: WES) and Transurban Group (ASX: TCL). But I want to talk about Medibank Private Ltd (ASX: MPL) and the new dividend that was just revealed.

Yep, just like Telstra and Wesfarmers, Medibank reported its latest earnings to the markets this morning. As we covered, it was a mixed set of numbers that the ASX 200 private health insurance stock came up with.

Medibank reported a 5.5% rise in group revenues to $4.5 billion. Group operating profit increased 6% to $381.7 million, although underlying net profit after tax (NPAT) was effectively unchanged at $297.8 million.

Investors don't seem to be impressed, to be frank, with the Medibank Private share price, which is currently down a nasty 6.16% at $4.50 a share. Saying that, the company is essentially now back to where it was on Tuesday, before yesterday's near-6% share price spike. This spike came after news that the government will allow private health insurers to hike premiums by at least 4.41% from April. That's the largest premium increase Australians have seen in many years.

But let's dig into Medibank's new dividend announcement today.

Stethoscope with a piggy bank and hundred dollar notes.

Image source: Getty Images

Medibank shares slip despite dividend hike

In some pleasing news for income investors, Medibank has just revealed that it will hike its next dividend. The company revealed an interim dividend of 8.3 cents per share as its first payout of 2026. Like most dividends from Medibank Private, it will come with full franking credits attached.

This interim dividend represents a 6.4% increase over the 7.8 cents per share payout that Medibank doled out this time last year. Together with the final dividend of 10.2 cents per share from October last year, it takes Medibank's 12-month dividend total to 18.5 cents per share, a record high for the company.

It is a significant payout on another level for Medibank. This latest dividend is the sixth consecutive payout in a row that has been increased annually. That's quite a streak that Medibank is cultivating.

Medibank shares will trade ex-dividend for this payout on 26 February next week. Payday has then been scheduled for 18 March next month. Medibank is not running a dividend reinvestment plan for this dividend, so investors will have to take it in cash.

As it stands today, Medibank Private shares are trading on a trailing dividend yield of 4%. However, with this new payout revealed, we can give the stock a forward dividend yield of 4.11%.

Motley Fool contributor Sebastian Bowen has positions in Wesfarmers. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Transurban Group and Wesfarmers. The Motley Fool Australia has positions in and has recommended Telstra Group and Transurban Group. The Motley Fool Australia has recommended Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three businesswomen collaborate around a table.
Healthcare Shares

Clarity Pharmaceuticals reports clinical progress in June 2026 quarter

Clarity Pharmaceuticals reported $178.3 million in cash and strong clinical progress for the June 2026 quarter.

Read more »

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

Mesoblast FY26 earnings: Ryoncil revenue up, new trial milestones for ASX:MSB

Mesoblast reported a strong full year with US$115 million in Ryoncil revenue and advanced key clinical trials for future growth.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

CSL launches clinical trials for new plasma manufacturing process

CSL will launch clinical trials of its new Horizon 2 plasma process in 2027, seeking enhanced yields and regulatory approvals.

Read more »

A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Should I buy CSL shares before the end of July?

Here's what I expect from the beaten-down biotech stock next month.

Read more »

Concept image of a businessman riding a bull on an upwards arrow.
Broker Notes

Up 1,250% in a year, why 4DMedical shares can keep charging higher

A top analyst forecasts more outperformance from the surging shares.

Read more »

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused.
Healthcare Shares

Down 31%: Is there any chance of a rebound from ResMed shares?

The ASX healthcare share has lost 31% over the past 12 months.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

If I invested $5,000 in this ASX healthcare stock 12 months ago, I'd have over $67k today!

This ASX healthcare stock is bucking the trend.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Down 35% for the year, is it time to buy this beaten-down ASX biotech?

Stronger revenue numbers signal potential upside.

Read more »